Skip to main content
ALUR
NYSE Industrial Applications And Services

Allurion Technologies Receives Landmark FDA Approval for Gastric Balloon System, Unlocking U.S. Obesity Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
10
Price
$1.605
Mkt Cap
$13.384M
52W Low
$0.95
52W High
$4.18
52W Position info
69% above low
Off High info
62% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ALUR sits 69% above its 52-week low of $0.95.

Summary

Allurion Technologies announced it received U.S. FDA Premarket Approval (PMA) for its Allurion Gastric Balloon System, a non-invasive weight loss solution, opening access to a large U.S. market.


Key Events · Product Development and Regulatory · ALUR

  • FDA PMA Approval Granted

    The U.S. Food and Drug Administration (FDA) granted Premarket Approval (PMA) for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule.

  • Access to Significant U.S. Market

    The approval provides Allurion with access to approximately 80 million Americans with obesity (BMI 30-40 kg/m2) who have had unsuccessful weight loss attempts.

  • Non-Invasive Weight Loss Solution

    The Allurion Smart Capsule is swallowed in a 15-minute office visit, requiring no surgery, endoscopy, or anesthesia, and resides in the stomach for approximately four months.

  • Alternative to GLP-1s and Bariatric Surgery

    The system is positioned as a safe and effective alternative or complement to GLP-1 medications and bariatric surgery, addressing patient needs for different treatment options.


Analysis · ALUR · Industrial Applications And Services

This filing announces a pivotal FDA Premarket Approval (PMA) for Allurion's Gastric Balloon System, featuring the Smart Capsule. This approval is a transformative event for the company, granting access to the substantial U.S. market of approximately 80 million adults with obesity. The product's non-invasive nature (swallowable, no surgery, endoscopy, or anesthesia) positions it as a significant alternative or complement to existing weight loss solutions like GLP-1s and bariatric surgery. This regulatory milestone is expected to be a major catalyst for future growth and commercialization efforts, fundamentally altering the company's market potential and investment thesis.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 40% of the 30 measured filings Wiseek scored 10 moved their stock by 5% or more by the next session's close. The median move was +0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALUR was trading at $1.61 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $0.95 to $4.18. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALUR - Latest Insights

ALUR
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.851
Real-time Price: $0.0020 info
Change: Reverse Stock Split info
Market Cap: $2.001K info
ALUR
May 08, 2026, 12:29 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.686
Real-time Price: $0.0020 info
Change: Reverse Stock Split info
Market Cap: $2.001K info
ALUR
Apr 20, 2026, 8:37 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.0020 info
Change: Reverse Stock Split info
Market Cap: $2.001K info
ALUR
Mar 30, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
10
Price at Filing: $0.7746
Real-time Price: $0.0020 info
Change: Reverse Stock Split info
Market Cap: $2.001K info
ALUR
Mar 12, 2026, 5:11 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.360
Real-time Price: $0.0020 info
Change: Reverse Stock Split info
Market Cap: $2.001K info